Matrifen (Fentanyl)

Fentanyl acts as a potent agonist at mu‑opioid receptors in the brain and spinal cord. By activating these receptors, it inhibits the release of pain‑transmitting neurotransmitters, reduces neuronal excitability, and thereby provides strong analgesia throughout the duration of the patch.

The appropriate dose of Matrifen is determined by the prescribing clinician based on the patient’s opioid tolerance, pain severity, and clinical response. The prescriber selects the specific patch strength and duration that best matches the individual’s therapeutic needs.

Safety data for fentanyl transdermal patches in pregnancy and lactation are limited. Because opioids can cross the placenta and enter breast milk, Matrifen is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To order Matrifen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Matrifen delivers fentanyl, which is significantly more potent than morphine on a milligram‑per‑milligram basis. The transdermal system offers steady plasma concentrations, reducing peaks and troughs seen with oral dosing. Compared with oral opioids, the patch may improve adherence but requires careful skin assessment and monitoring for respiratory depression.

Store Matrifen at room temperature, below 25 °C, in its original sealed packaging. Keep the patches away from direct sunlight, moisture, and heat sources. Do not expose the product to temperatures above the recommended range, as this may affect drug stability and delivery performance.

Matrifen is applied to clean, dry, hair‑free skin on the upper torso, upper arm, or thigh. The patch should be pressed firmly for at least 30 seconds to ensure adhesion, then covered with a protective dressing if needed. It remains in place for the prescribed duration (usually 72 hours) before removal and replacement with a new patch.

The most serious risks include respiratory depression, which can be life‑threatening, especially in opioid‑naïve patients or when combined with other depressants. Other critical concerns are severe hypotension, adrenal insufficiency, and the potential for overdose if the patch is misused or applied to damaged skin.

Matrifen should not be used by patients with known hypersensitivity to fentanyl or any patch components, those with severe respiratory insufficiency, untreated obstructive sleep apnea, or acute narrow‑angle glaucoma. It is also contraindicated in individuals who are opioid‑naïve and require rapid titration under close medical supervision.